Dr. Srivastava has co-founded a biotechnology company to help find new cures for many human diseases and one of the developmental genes whose role he discovered, Thymosin β4, is currently in clinical trials for patients suffering
ischemic damage to the heart.
We are now moving this discovery into Phase II clinical trials (FDA approved) in patients suffering
ischemic damage to the heart.
Not exact matches
Earlier studies in STEMI patients showed that
ischemic postconditioning improved ST - segment resolution — an important marker of arterial blockage on electrocardiogram — reduced
damage to heart muscle, and in some patients limited the extent of reperfusion injury.
In animals, these cells quickly repaired vascular
damage, cutting the death rate after a
heart attack in half and restoring the blood flow
to ischemic limbs that might otherwise have
to be amputated.
Okyanos cardiac cell therapy targets the restoration of blood flow
to the
heart and repairs
damaged heart tissue caused by
heart attack or
ischemic and non-
ischemic heart disease.